A graphical summary illustrates the strategy used to identify CYP2D6 as a target for collateral lethality, which is driven by the widespread occurrence of loss of heterozygosity in cancer genomes. (IMAGE)
Uppsala University
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.